dupilumab治疗的慢性鼻窦炎伴鼻息肉患者很少需要再次内镜鼻窦手术
这项前瞻性观察队列研究纳入394例接受dupilumab治疗的成人CRSwNP患者,发现仅1.8%因反应不足需再次ESS,且术后疾病控制多数仍不理想。
要点
- dupilumab治疗CRSwNP时因反应不足需再次ESS的比例仅为1.8%。
- 需再次手术者多为男性、基线血清IgE较低、距末次ESS时间较长。
- 再次ESS后除2例外疾病控制仍不充分,提示该亚组需要新疗法。
核心结论
- dupilumab治疗下因CRSwNP未控制而需再次ESS作为escape治疗的情况很少见。
- 对dupilumab反应不足者行再次ESS的结果令人失望,提示需开发新治疗。
研究设计与样本
- 前瞻性观察性队列研究,纳入394例生物制剂初治的成人CRSwNP患者,按EPOS2020指征接受dupilumab治疗。
- 将因dupilumab反应不足行ESS者与仍在治疗者比较基线人口学和临床特征。
主要发现
- 394例中41例(10.4%)停用dupilumab,其中10例(2.5%)因反应不足停药。
- 7例(占总1.8%)接受了再次ESS。
- 需再次手术者显著更多为男性、基线血清IgE较低、距末次ESS时间较长。
临床怎么用
- dupilumab治疗CRSwNP时再次ESS需求低,但一旦因反应不足需手术,应预期术后控制可能仍不佳。
- 对dupilumab反应不足的有限亚组,应考虑探索新治疗而非仅依赖再次ESS。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study was set out to investigate the incidence of revision endoscopic sinus surgery (ESS) in patients treated with dupilumab for chronic rhinosinusitis with nasal polyps (CRSwNP). Furthermore, clinical course and outcome of surgery of these patients was described. METHODS: A prospective observational cohort study of adult and biological-naive patients with CRSwNP treated with dupilu-mab as per EPOS2020 indication criteria (at least one previous ESS) was undertaken. Patients that had ESS due to an insufficient response to dupilumab were compared to those still on treatment. Baseline demographics and clinical characteristics (such as evidence of type 2 inflammation, SNOT-22 score, and nasal polyp score) were compared between the two groups. Furthermore, clinical measurements at indication of surgery, type of surgery and clinical outcomes are described. RESULTS: Discontinuation of dupilumab treatment occurred in 41 out of 394 (10.4%) patients, of whom 10 (2.5%) stopped because of an insufficient response. Seven of these patients (1.8% of total) underwent revision ESS. The patients that needed revision sur-gery for uncontrolled CRSwNP were significantly more often male, had lower baseline serum IgE and longer time since the last ESS compared to those still on dupilumab. Despite revision ESS, disease control postoperatively was insufficient in all but two patients. CONCLUSIONS: Revision endoscopic sinus surgery as an escape-treatment for uncontrolled CRSwNP despite dupilumab is rarely needed. The disappointing results of revision ESS for patients with uncontrolled CRSwNP who failed dupilumab calls for new treatments for this limited group.
引用
- Kemp P, Otten JJ, Elzinga HBE, et al. Revision endoscopic sinus surgery is rarely needed in dupilumab-treated chronic rhinosinusitis with nasal polyps. Rhinology. 2026. PMID: 41892394. doi:10.4193/Rhin24.401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。